Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...
The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...
MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.
AstraZeneca has reported positive results from a Phase III trial that evaluated Truqap combined with abiraterone and ADT for ...
The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback